ClinicalTrials.gg
CompletedNCT02738879Updated Feb 25, 2019Results posted

Randomized Sitagliptin Withdrawal Study (MK-0431-845)

A Phase 3 interventional study of Sitagliptin and Placebo to sitagliptin in Type 2 Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-02-25.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
746
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.

Enrollment
13th of 197
746 · median 102
Started
2016
with 10 others
Phase 3
74 of 198
none open now
Registered
169th of 198
by date
Lead sponsor
70 of 198
Merck Sharp & Dohme LLC

Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 13th largest by enrollment of the 197 interventional ones that give a count, is one of 11 that started in 2016, is one of 74 in phase 3, and was the 169th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About sitagliptin

sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This is a trial of continuing sitagliptin versus withdrawing sitagliptin in participants with Type 2 diabetes mellitus (T2DM) and inadequate glycemic control who initiate and titrate insulin glargine (LANTUS®) based on a treat-to-target algorithm to achieve fasting glucose levels of 72-100 mg/dL (4-5.6 mmol/L). A primary hypothesis of this trial is that after 30 weeks, continuing sitagliptin results in a greater reduction of hemoglobin A1C (A1C) relative to withdrawing sitagliptin.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have T2DM based on American Diabetes Association guidelines
  • Be on one of the following treatment regimens:

    1. Stable dose of sitagliptin (100 mg/day) and metformin IR or XR (metformin) (≥1500 mg/day) either co-administered or as a fixed dose combination (FDC) for ≥12 weeks with between 7.5% and 11.0%, inclusive.

      OR

    2. Stable dose of metformin (≥1500 mg/day) and another dipeptidyl peptidase-4 (DPP-4) inhibitor (at maximum labeled dose, other than sitagliptin, either co-administered or as a FDC, for ≥12 weeks with A1C between 7.5% and 11.0%, inclusive.

      OR

    3. Stable dose of sitagliptin (100 mg/day) and metformin (≥1500 mg/day) either co administered or as a FDC, and a sulfonylurea for ≥12 weeks OR stable dose of metformin (≥1500 mg/day) and a sulfonylurea administered as a FDC and sitagliptin (100 mg/day) with A1C between 7.0% and 10.0%, inclusive.

      OR

    4. Stable dose of metformin (≥1500 mg/day) and another DPP-4 inhibitor (at maximum labeled dose), other than sitagliptin, either co-administered or as a FDC, and a sulfonylurea for ≥12 weeks OR stable dose of metformin (≥1500 mg/day) and a sulfonylurea administered as a FDC and another DPP-4 inhibitor other than sitagliptin with A1C between 7.0% and 10.0%, inclusive OR
    5. Stable dose of metformin (≥1500 mg/day) and a sulfonylurea either co-administered or as a FDC for ≥12 weeks with A1C between 7.5% and 11.0%, inclusive.
  • Meet one of the following categories:

    1. The participant is a male
    2. The participant is a female who is not of
    3. The participant is a female who is of reproductive potential and agrees to avoid becoming pregnant while receiving study drug and for 14 days after the last dose of study drug by practicing abstinence from heterosexual activity OR use (or have her partner use) acceptable during heterosexual activity

Exclusion criteria

Exclusion Criteria:

  • Has been treated with any anti-hyperglycemic agent (AHA) other than protocol-specified agents (i.e., other than metformin, DPP-4 inhibitor, or sulfonylurea agent) within the prior 12 weeks.
  • Has a history of 2 or more episodes of hypoglycemia resulting in seizure, coma, or loss of consciousness, OR has had recurrent (≥3 times per week) episodes of hypoglycemia over the past 8 weeks.
  • Has a history of type 1 diabetes mellitus (T1DM) or ketoacidosis, or has a history of latent diabetes of adults (LADA), is assessed by the investigator as possibly having T1DM or LADA confirmed with a C-peptide \<0.7 ng/mL (\<0.23 nmol/L), or has a history of other specific types of diabetes (e.g., genetic syndromes, secondary pancreatic diabetes, diabetes due to endocrinopathies, drug- or chemical-induced, or post-organ transplant).
  • Is assessed by the investigator to be not appropriate for, or does not agree to target, a fasting glucose of 72-100 mg/dL (4.0-5.6 mmol/L).
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
746 participants (actual)

Study arms

  • Experimental
    Sitagliptin

    Sitagliptin 100 mg, oral, once daily for 30 weeks

    Drug: Sitagliptin · Drug: Metformin · Drug: Metformin XR · Drug: Insulin glargine

  • Placebo comparator
    Placebo

    Placebo to sitagliptin, 100 mg, oral, once daily for 30 weeks

    Drug: Placebo to sitagliptin · Drug: Metformin · Drug: Metformin XR · Drug: Insulin glargine

Interventions

  • Sitagliptin 100 mg, oral, once daily for 30 weeks

    Also known as: Januvia®

  • DrugPlacebo to sitagliptin

    Placebo to sitagliptin, 100 mg, oral, once daily for 30 weeks

  • At least 1500 mg/day, oral, twice daily for participants entering the study on immediate-release metformin + sitagliptin or a fixed dose combination (FDC).

  • At least 1500 mg/day, oral, once daily for participants entering the study on extended-release metformin + sitagliptin or a FDC.

  • Insulin glargine (LANTUS®) initiated at 10 units and titrated based on a treat-to-target algorithm to achieve fasting glucose levels of 72-100 mg/dL (4-5.6 mmol/L); administered once daily subcutaneously.

    Also known as: LANTUS®)

06

What researchers measure

Primary outcomes

  1. Change From Baseline in A1C at Week 30

    A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Thus, this change from baseline reflects the Week 30 A1C minus the Week 0 A1C.

    Time frame: Baseline and Week 30

  2. Event Rate of Documented Symptomatic Hypoglycemia With Blood Glucose ≤70 mg/dL (≤3.9 mmol/L)

    Documented symptomatic hypoglycemia is defined as an event during which typical symptoms of hypoglycemia are accompanied by a measured (e.g., by fingerstick) plasma glucose concentration ≤70 mg/dL (≤3.9 mmol/L). The event rate was the total number of events divided by follow-up time (participant-years), including multiple events from the same participant.

    Time frame: Up to 30 weeks

  3. Percentage of Participants Who Discontinued Study Drug Due to an AE

    An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.

    Time frame: Up to 30 weeks

  4. Percentage of Participants Who Experienced One or More Adverse Events (AEs)

    An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.

    Time frame: Up to 32 weeks

Secondary outcomes

  1. Percentage of Participants With Events of Documented Symptomatic Hypoglycemia With Blood Glucose ≤70 mg/dL (≤3.9 mmol/L)

    Documented symptomatic hypoglycemia is defined as an event during which typical symptoms of hypoglycemia are accompanied by a measured (e.g., by fingerstick) plasma glucose concentration ≤70 mg/dL (≤3.9 mmol/L). The incidence (number of participants with ≥1 event divided by number of participants) of documented symptomatic hypoglycemia was determined.

    Time frame: Up to 30 weeks

  2. Change From Baseline in Total Daily Insulin Dose (Units) at Week 30

    Change from baseline reflects the Week 30 total daily insulin dose minus the Week 0 total daily insulin dose. The Week 0 total daily insulin dose was 0, by definition, because insulin was not administered at baseline.

    Time frame: Baseline and Week 30

  3. Event Rate of Documented Hypoglycemia With Blood Glucose ≤70 mg/dL (≤3.9 mmol/L)

    Documented hypoglycemia is defined by a measured (e.g., by fingerstick) plasma glucose concentration ≤70 mg/dL (≤3.9 mmol/L). The event rate was the total number of events divided by follow-up time (participant-years), including multiple events from the same participant.

    Time frame: Up to 30 weeks

  4. Event Rate of Documented Hypoglycemia With Blood Glucose <56 mg/dL (≤3.1 mmol/L)

    Documented hypoglycemia is defined by a measured (e.g., by fingerstick) plasma glucose concentration \<56 mg/dL (≤3.1 mmol/L). The event rate was the total number of events divided by follow-up time (participant-years), including multiple events from the same participant.

    Time frame: Up to 30 weeks

  5. Percentage of Participants With Documented Hypoglycemia With Blood Glucose <56 mg/dL (≤3.1 mmol/L)

    Documented hypoglycemia is defined by a measured (e.g., by fingerstick) plasma glucose concentration \<56 mg/dL (≤3.1 mmol/L).

    Time frame: Up to 30 weeks

  6. Percentage of Participants With A1C Goal <7.0% (<53 mmol/Mol) at Week 30

    A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100.

    Time frame: Week 30

  7. Change From Baseline in Fasting Plasma Glucose (FPG) at Week 30

    Blood glucose was measured on a fasting basis. Blood was drawn at predose on Day 1 and after 30 weeks of treatment to determine change in plasma glucose levels (i.e., FPG at Week 30 minus FPG at Week 0).

    Time frame: Baseline and Week 30

  8. Event Rate of Documented Symptomatic Hypoglycemia With Blood Glucose <56 mg/dL (≤3.1 mmol/L)

    Documented symptomatic hypoglycemia is defined as an event during which typical symptoms of hypoglycemia are accompanied by a measured (e.g., by fingerstick) plasma glucose concentration \<56 mg/dL (≤3.1 mmol/L). The event rate was the total number of events divided by follow-up time (participant-years), including multiple events from the same participant.

    Time frame: Up to 30 weeks

  9. Percentage of Participants With Documented Hypoglycemia With Blood Glucose ≤70 mg/dL (≤3.9 mmol/L)

    Documented hypoglycemia is defined by a measured (e.g., by fingerstick) plasma glucose concentration ≤70 mg/dL (≤3.9 mmol/L).

    Time frame: Up to 30 weeks

  10. Percentage of Participants With Documented Symptomatic Hypoglycemia With Blood Glucose <56 mg/dL (≤3.1 mmol/L)

    Documented symptomatic hypoglycemia is defined as an event during which typical symptoms of hypoglycemia are accompanied by a measured (e.g., by fingerstick) plasma glucose concentration \<56 mg/dL (≤3.1 mmol/L).

    Time frame: Up to 30 weeks

  11. Percentage of Participants With A1C Goal <7.0% (<53 mmol/Mol at Week 30 and No Documented Hypoglycemia With Blood Glucose ≤70 mg/dL (≤3.9 mmol/L) up to Week 30

    A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100.

    Time frame: Week 30

07

Results

Posted Feb 25, 2019

Participant flow

A total of 746 participants were randomized across 149 study sites in 22 countries.

Participant flow — Overall Study
MilestoneSitagliptinPlacebo
Started374372
Treated373370
Completed361347
Not completed1325
Withdrew: Adverse event11
Withdrew: Death02
Withdrew: Lost to follow-up15
Withdrew: Protocol violation13
Withdrew: Physician decision34
Withdrew: Pregnancy01
Withdrew: Screen failure12
Withdrew: Site discontinued study participation10
Withdrew: Withdrawal by subject57

Outcome measures

PrimaryChange From Baseline in A1C at Week 30

A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Thus, this change from baseline reflects the Week 30 A1C minus the Week 0 A1C.

Time frame:
Baseline and Week 30
Reported as:
Least squares mean · Percent A1C
Change From Baseline in A1C at Week 30
Percent A1CSitagliptinPlacebo
Change From Baseline in A1C at Week 30-1.88 ± -1.98-1.42 ± -1.52
Statistical analysis
  • Sitagliptin vs Placebo · LDA · Between group difference in the lsm: -0.46 · 95% CI -0.58 to -0.34
  • Sitagliptin vs Placebo · LDA · p = < 0.001 · Between group difference in the lsm: -0.46 · 95% CI -0.58 to -0.34
PrimaryEvent Rate of Documented Symptomatic Hypoglycemia With Blood Glucose ≤70 mg/dL (≤3.9 mmol/L)

Documented symptomatic hypoglycemia is defined as an event during which typical symptoms of hypoglycemia are accompanied by a measured (e.g., by fingerstick) plasma glucose concentration ≤70 mg/dL (≤3.9 mmol/L). The event rate was the total number of events divided by follow-up time (participant-years), including multiple events from the same participant.

Time frame:
Up to 30 weeks
Reported as:
Number · Events/Participant-Years
Event Rate of Documented Symptomatic Hypoglycemia With Blood Glucose ≤70 mg/dL (≤3.9 mmol/L)
Events/Participant-YearsSitagliptinPlacebo
Event Rate of Documented Symptomatic Hypoglycemia With Blood Glucose ≤70 mg/dL (≤3.9 mmol/L)1.55 ± 1.222.12 ± 1.70
Statistical analysis
  • Sitagliptin vs Placebo · Negative Binomial Model · p = = 0.039 · Event rate ratio: 0.73 · 95% CI 0.54 to 0.98
PrimaryPercentage of Participants Who Discontinued Study Drug Due to an AE

An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.

Time frame:
Up to 30 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants Who Discontinued Study Drug Due to an AE
Percentage of participantsSitagliptinPlacebo
Percentage of Participants Who Discontinued Study Drug Due to an AE1.31.6
Statistical analysis
  • Sitagliptin vs Placebo · Miettinen & Nurminen · Between group difference in percentages: -0.3 · 95% CI -2.3 to 1.7
SecondaryPercentage of Participants With Events of Documented Symptomatic Hypoglycemia With Blood Glucose ≤70 mg/dL (≤3.9 mmol/L)

Documented symptomatic hypoglycemia is defined as an event during which typical symptoms of hypoglycemia are accompanied by a measured (e.g., by fingerstick) plasma glucose concentration ≤70 mg/dL (≤3.9 mmol/L). The incidence (number of participants with ≥1 event divided by number of participants) of documented symptomatic hypoglycemia was determined.

Time frame:
Up to 30 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants With Events of Documented Symptomatic Hypoglycemia With Blood Glucose ≤70 mg/dL (≤3.9 mmol/L)
Percentage of participantsSitagliptinPlacebo
Percentage of Participants With Events of Documented Symptomatic Hypoglycemia With Blood Glucose ≤70 mg/dL (≤3.9 mmol/L)33.5 ± 28.537.7 ± 32.7
Statistical analysis
  • Sitagliptin vs Placebo · Miettinen and Nurminen · p = = 0.250 · Between group difference in percentages: -4.1 · 95% CI -11.2 to 2.9
SecondaryChange From Baseline in Total Daily Insulin Dose (Units) at Week 30

Change from baseline reflects the Week 30 total daily insulin dose minus the Week 0 total daily insulin dose. The Week 0 total daily insulin dose was 0, by definition, because insulin was not administered at baseline.

Time frame:
Baseline and Week 30
Reported as:
Least squares mean · Insulin Units
Change From Baseline in Total Daily Insulin Dose (Units) at Week 30
Insulin UnitsSitagliptinPlacebo
Change From Baseline in Total Daily Insulin Dose (Units) at Week 3053.2 ± 48.561.3 ± 56.5
Statistical analysis
  • Sitagliptin vs Placebo · LDA model · p = = 0.016 · Between group difference in the lsm: -8.0 · 95% CI -14.6 to -1.5
SecondaryEvent Rate of Documented Hypoglycemia With Blood Glucose ≤70 mg/dL (≤3.9 mmol/L)

Documented hypoglycemia is defined by a measured (e.g., by fingerstick) plasma glucose concentration ≤70 mg/dL (≤3.9 mmol/L). The event rate was the total number of events divided by follow-up time (participant-years), including multiple events from the same participant.

Time frame:
Up to 30 weeks
Reported as:
Number · Events/Participant-Years
Event Rate of Documented Hypoglycemia With Blood Glucose ≤70 mg/dL (≤3.9 mmol/L)
Events/Participant-YearsSitagliptinPlacebo
Event Rate of Documented Hypoglycemia With Blood Glucose ≤70 mg/dL (≤3.9 mmol/L)5.05 ± 4.346.21 ± 5.33
Statistical analysis
  • Sitagliptin vs Placebo · Negative Binomial Model · p = = 0.041 · Event rate ratio: 0.81 · 95% CI 0.67 to 0.99
SecondaryEvent Rate of Documented Hypoglycemia With Blood Glucose <56 mg/dL (≤3.1 mmol/L)

Documented hypoglycemia is defined by a measured (e.g., by fingerstick) plasma glucose concentration \<56 mg/dL (≤3.1 mmol/L). The event rate was the total number of events divided by follow-up time (participant-years), including multiple events from the same participant.

Time frame:
Up to 30 weeks
Reported as:
Number · Events/Participant-Years
Event Rate of Documented Hypoglycemia With Blood Glucose <56 mg/dL (≤3.1 mmol/L)
Events/Participant-YearsSitagliptinPlacebo
Event Rate of Documented Hypoglycemia With Blood Glucose <56 mg/dL (≤3.1 mmol/L)0.30 ± 0.200.36 ± 0.25
Statistical analysis
  • Sitagliptin vs Placebo · Negative Binomial Model · p = = 0.473 · Event rate ratio: 0.83 · 95% CI 0.51 to 1.37
SecondaryPercentage of Participants With Documented Hypoglycemia With Blood Glucose <56 mg/dL (≤3.1 mmol/L)

Documented hypoglycemia is defined by a measured (e.g., by fingerstick) plasma glucose concentration \<56 mg/dL (≤3.1 mmol/L).

Time frame:
Up to 30 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants With Documented Hypoglycemia With Blood Glucose <56 mg/dL (≤3.1 mmol/L)
Percentage of participantsSitagliptinPlacebo
Percentage of Participants With Documented Hypoglycemia With Blood Glucose <56 mg/dL (≤3.1 mmol/L)12.4 ± 8.913.6 ± 10.0
Statistical analysis
  • Sitagliptin vs Placebo · Miettinen and Nurminen · p = = 0.624 · Between group difference in percentages: -1.2 · 95% CI -6.2 to 3.7
SecondaryPercentage of Participants With A1C Goal <7.0% (<53 mmol/Mol) at Week 30

A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100.

Time frame:
Week 30
Reported as:
Number · Percentage of participants
Percentage of Participants With A1C Goal <7.0% (<53 mmol/Mol) at Week 30
Percentage of participantsSitagliptinPlacebo
Percentage of Participants With A1C Goal <7.0% (<53 mmol/Mol) at Week 3054.235.4
Statistical analysis
  • Sitagliptin vs Placebo · Miettinen and Nurminen · p = < 0.001 · Between group difference in percentages: 18.8 · 95% CI 11.6 to 25.7
SecondaryChange From Baseline in Fasting Plasma Glucose (FPG) at Week 30

Blood glucose was measured on a fasting basis. Blood was drawn at predose on Day 1 and after 30 weeks of treatment to determine change in plasma glucose levels (i.e., FPG at Week 30 minus FPG at Week 0).

Time frame:
Baseline and Week 30
Reported as:
Least squares mean · mg/dL
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 30
mg/dLSitagliptinPlacebo
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 30-84.8 ± -90.0-78.3 ± -83.5
Statistical analysis
  • Sitagliptin vs Placebo · LDA · p = = 0.020 · Between group difference in the lsm: -6.5 · 95% CI -11.9 to -1.0
PrimaryPercentage of Participants Who Experienced One or More Adverse Events (AEs)

An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.

Time frame:
Up to 32 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants Who Experienced One or More Adverse Events (AEs)
Percentage of participantsSitagliptinPlacebo
Percentage of Participants Who Experienced One or More Adverse Events (AEs)57.960.0
Statistical analysis
  • Sitagliptin vs Placebo · Miettinen & Nurminen · Between group difference in percentages: -2.1 · 95% CI -9.1 to 5.0
SecondaryEvent Rate of Documented Symptomatic Hypoglycemia With Blood Glucose <56 mg/dL (≤3.1 mmol/L)

Documented symptomatic hypoglycemia is defined as an event during which typical symptoms of hypoglycemia are accompanied by a measured (e.g., by fingerstick) plasma glucose concentration \<56 mg/dL (≤3.1 mmol/L). The event rate was the total number of events divided by follow-up time (participant-years), including multiple events from the same participant.

Time frame:
Up to 30 weeks
Reported as:
Number · Events/Participant-Years
Event Rate of Documented Symptomatic Hypoglycemia With Blood Glucose <56 mg/dL (≤3.1 mmol/L)
Events/Participant-YearsSitagliptinPlacebo
Event Rate of Documented Symptomatic Hypoglycemia With Blood Glucose <56 mg/dL (≤3.1 mmol/L)0.17 ± 0.100.22 ± 0.14
Statistical analysis
  • Sitagliptin vs Placebo · Negative Binomial Model · p = = 0.394 · Event rate ratio: 0.76 · 95% CI 0.40 to 1.44
SecondaryPercentage of Participants With Documented Hypoglycemia With Blood Glucose ≤70 mg/dL (≤3.9 mmol/L)

Documented hypoglycemia is defined by a measured (e.g., by fingerstick) plasma glucose concentration ≤70 mg/dL (≤3.9 mmol/L).

Time frame:
Up to 30 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants With Documented Hypoglycemia With Blood Glucose ≤70 mg/dL (≤3.9 mmol/L)
Percentage of participantsSitagliptinPlacebo
Percentage of Participants With Documented Hypoglycemia With Blood Glucose ≤70 mg/dL (≤3.9 mmol/L)66.8 ± 61.968.0 ± 63.2
Statistical analysis
  • Sitagliptin vs Placebo · Miettinen and Nurminen · p = = 0.740 · Between group difference in percentages: -1.2 · 95% CI -8.2 to 5.8
SecondaryPercentage of Participants With Documented Symptomatic Hypoglycemia With Blood Glucose <56 mg/dL (≤3.1 mmol/L)

Documented symptomatic hypoglycemia is defined as an event during which typical symptoms of hypoglycemia are accompanied by a measured (e.g., by fingerstick) plasma glucose concentration \<56 mg/dL (≤3.1 mmol/L).

Time frame:
Up to 30 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants With Documented Symptomatic Hypoglycemia With Blood Glucose <56 mg/dL (≤3.1 mmol/L)
Percentage of participantsSitagliptinPlacebo
Percentage of Participants With Documented Symptomatic Hypoglycemia With Blood Glucose <56 mg/dL (≤3.1 mmol/L)7.6 ± 4.98.3 ± 5.4
Statistical analysis
  • Sitagliptin vs Placebo · Miettinen and Nurminen · p = = 0.712 · Between group difference in percentages: -0.7 · 95% CI -4.7 to 3.2
SecondaryPercentage of Participants With A1C Goal <7.0% (<53 mmol/Mol at Week 30 and No Documented Hypoglycemia With Blood Glucose ≤70 mg/dL (≤3.9 mmol/L) up to Week 30

A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100.

Time frame:
Week 30
Reported as:
Number · Percentage of participants
Percentage of Participants With A1C Goal <7.0% (<53 mmol/Mol at Week 30 and No Documented Hypoglycemia With Blood Glucose ≤70 mg/dL (≤3.9 mmol/L) up to Week 30
Percentage of participantsSitagliptinPlacebo
Percentage of Participants With A1C Goal <7.0% (<53 mmol/Mol at Week 30 and No Documented Hypoglycemia With Blood Glucose ≤70 mg/dL (≤3.9 mmol/L) up to Week 3015.310.0
Statistical analysis
  • Sitagliptin vs Placebo · Miettinen and Nurminen · p = = 0.030 · Between group difference in percentages: 5.3 · 95% CI 0.5 to 10.1

Adverse events

Collected over Up to 32 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sitagliptin0/373 (0%)14/373 (3.8%)79/373 (21.2%)
Placebo2/370 (0.5%)18/370 (4.9%)72/370 (19.5%)
Most frequent serious events
Showing 10 of 32
Most frequent serious events
EventSitagliptinPlacebo
Cerebrovascular accidentNervous system disorders0/3732/370
Ischaemic strokeNervous system disorders0/3732/370
Acute myocardial infarctionCardiac disorders1/3731/370
Coronary artery diseaseCardiac disorders1/3731/370
Myocardial infarctionCardiac disorders0/3731/370
PhimosisCongenital, familial and genetic disorders0/3731/370
ColitisGastrointestinal disorders0/3731/370
BronchitisInfections and infestations0/3731/370
PyelonephritisInfections and infestations0/3731/370
TracheitisInfections and infestations0/3731/370
Most frequent other events
Most frequent other events
EventSitagliptinPlacebo
HypoglycaemiaMetabolism and nutrition disorders35/37324/370
NasopharyngitisInfections and infestations24/37332/370
HeadacheNervous system disorders25/37319/370

Baseline characteristics

The overall number of baseline participants included all randomized participants.

Age, Continuous
Age, Continuous(years)SitagliptinPlaceboTotal
Mean58.5 ± 9.558.1 ± 9.758.3 ± 9.6
Age, Customized
Age, Customized(Participants)SitagliptinPlaceboTotal
In utero000
Preterm newborn infants (gestational age < 37 wks)000
Newborns (0-27 days)000
Infants and toddlers (28 days-23 months)000
Children (2-11 years)000
Adolescents (12-17 years)000
Adults (18-64 years)275272547
From 65-84 years99100199
85 years and over000
Sex: Female, Male
Sex: Female, Male(Participants)SitagliptinPlaceboTotal
Female204181385
Male170191361
Race (NIH/OMB)
Race (NIH/OMB)(Participants)SitagliptinPlaceboTotal
American Indian or Alaska Native191837
Asian423779
Native Hawaiian or Other Pacific Islander617
Black or African American121224
White259270529
More than one race343468
Unknown or Not Reported202
Geographic Region
Geographic Region(Participants)SitagliptinPlaceboTotal
Asia362662
Europe158172330
Latin America8583168
North America8078158
Other151328
Hemoglobin A1C (A1C)
Hemoglobin A1C (A1C)(Percent A1C)SitagliptinPlaceboTotal
Mean8.8 ± 0.98.8 ± 1.08.8 ± 0.9
Fasting Plasma Glucose (FPG)
Fasting Plasma Glucose (FPG)(mg/dL)SitagliptinPlaceboTotal
Mean199.0 ± 50.8201.2 ± 51.8200.1 ± 51.3
Estimated Glomerular Filtration Rate
Estimated Glomerular Filtration Rate(mL/min/1.73 m^2)SitagliptinPlaceboTotal
Mean103.7 ± 30.3106.4 ± 28.1105.1 ± 29.2

2 further baseline measures are reported on the registry.

08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Roussel R, Duran-Garcia S, Zhang Y, Shah S, Darmiento C, Shankar RR, Golm GT, Lam RLH, O'Neill EA, Gantz I, Kaufman KD, Engel SS. Double-blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase-4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT-I Study. Diabetes Obes Metab. 2019 Apr;21(4):781-790. doi: 10.1111/dom.13574. Epub 2018 Dec 9. PubMed 30393950 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2016 to primary completion in Jan 2018, 20 months.

Results were first posted in Feb 2019, 1 year 1 month after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 20 months is close to that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 11, 2016
First posted
Apr 14, 2016
StartActual
May 9, 2016
Primary completionActual
Jan 22, 2018
CompletionActual
Jan 30, 2018
Results first posted
Feb 25, 2019
Last update
Feb 25, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 25, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02738879
Responsible party
Sponsor
First posted
Apr 14, 2016
Start date
May 9, 2016
Primary completion
Jan 22, 2018
Completion
Jan 30, 2018
Results posted
Feb 25, 2019
Last update
Feb 25, 2019

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sitagliptin

Start the discussion